Developmental Therapeutics Program
发育治疗计划
基本信息
- 批准号:10599095
- 负责人:
- 金额:$ 209.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-04-04 至 2027-01-31
- 项目状态:未结题
- 来源:
- 关键词:Acute leukemiaAdultAgeAgingAnimal Cancer ModelAnimal ModelAnimalsAutologousAwardBasic ScienceBiologicalBiological MarkersBiological ModelsBiotechnologyCancer CenterCancer Center Support GrantCancer ControlCancer Therapy Evaluation ProgramCaringCatchment AreaCell TherapyChildhoodClinicalClinical ResearchClinical TrialsClinical Trials NetworkCollaborationsColoradoColorectal CancerCommunity OutreachContractsDataDevelopmentDevelopmental Therapeutics ProgramDisciplineDiseaseDrug KineticsDrug MonitoringEarly Therapeutic-Clinical Trials NetworkEducational ActivitiesEducational workshopEnrollmentEvaluation ResearchExperimental ModelsFacultyFosteringFunctional disorderFundingFutureGoalsGrantHeadHead and Neck CancerHealth Services AccessibilityHematologic NeoplasmsHomeHospitalsImageImmunobiologyImmunotherapyImprove AccessIncubatorsInstitutionInstitutional Review BoardsInterventionInvestigationInvestigational TherapiesInvestmentsJournalsLaboratoriesLaboratory ResearchLeadLeadershipLinkMalignant NeoplasmsMentorsMetabolismModalityModelingMolecularNCI-Designated Cancer CenterOncologyOrganOrganoidsOutcomePaperPatient CarePatientsPediatric HematologyPediatric HospitalsPediatric Oncology GroupPeer ReviewPharmaceutical PreparationsPharmacogenomicsPhasePilot ProjectsPopulationPre-Clinical ModelPreclinical TestingProtocols documentationPublishingQuality of lifeRare DiseasesResearchResearch Peer ReviewResearch PersonnelResource SharingSamplingSchoolsScienceSmall Business Innovation Research GrantSolidSolid NeoplasmSystemTestingThe University of Colorado Cancer CenterTherapeuticTrainingTranslatingTranslational ResearchTranslationsUnited States Department of Veterans AffairsUnited States National Institutes of HealthUniversitiesValidationWorkXenograft procedurebench to bedsidebiopharmaceutical industrycancer clinical trialcancer preventioncareercellular oncologyclinical applicationclinical developmentcommercializationcommunity engagementcompanion animalcomparativedesigndrug developmentdrug discoveryearly phase clinical trialearly phase trialearly-career facultyexperiencefirst-in-humanhost neoplasm interactionimprovedin vivoinvestigator-initiated trialmature animalmelanomamembermolecular oncologymultidisciplinarynext generationnovelnovel anticancer drugnovel therapeutic interventionnovel therapeuticsoncology programoncology trialparticipant enrollmentpatient derived xenograft modelpatient populationpediatric patientspersonalized medicinepre-clinicalpreclinical developmentpreclinical studyprogramsrecruitsymposiumtooltreatment trial
项目摘要
ABSTRACT
The goal of the Developmental Therapeutics (DT) program is to translate basic scientific discovery to clinical
application to benefit patients of all ages, improving the quality of life for patients in the catchment area and
beyond. Members develop, test, and institute novel therapies in adult and pediatric patients with solid and
hematologic malignancies and lead collaborative, multi-institutional initiatives to establish new treatment
paradigms. The DT program serves the catchment area by improving access to care, and training the next
generation of cancer researchers, focusing on mentoring early-career faculty. The DT program had two added
points of focus as a result of the prior review: 1) enhancing investigator-initiated trials (IITs) by developing the
IIT incubator and prioritizing IITs in early-phase trial and disease-specific groups, particularly those developed
by mentored members. As a result, accruals to intervention treatment IITs increased 3-fold from 47 in 2016 to
140 in 2020. And 2) enhancing preclinical xenograft development to foster immunobiology/immunotherapy
discovery. DT funded pilot grants producing orphan disease PDXs, humanized models (HM) for colorectal
cancer, and an autologous HM in melanoma. With 78 members representing 18 departments and 4 schools, DT
holds $3.2M in NCI, $2.0M in other NIH, and $2.8M in other peer-reviewed funding, a 50% increase in peer-
reviewed research funding from $5.4M in 2016 to $8.0M in 2020. Since 2016, DT members enrolled 2688
subjects to 641 intervention treatment trials, an increase of 29%. DT members published 1000 peer-reviewed
cancer-related papers, of which 48% were collaborative (15% inter-; 17% intra-; 16% both) and 24% in journals
with an IF>10. Forty-seven percent (47%) of these represent collaborations with other NCI-designated cancer
centers. University of Colorado Cancer Center (UCCC) educational activities, training/career enhancement
activities, and shared resources (SRs) support are foundational to the DT's priorities of funding pilot grants that
emphasize “homegrown” therapies and bench-to-bedside application of discoveries. These investments led to
successful program project collaborations and multiple-PI funding across the UCCC. DT continues to expand
multi-stakeholder partnerships within UCCC and with key partners, including the University of Colorado Boulder
(UCB), Colorado State University (CSU), University of Colorado Hospital (UCH), Children's Hospital Colorado
(CHCO), and the Veterans Administration (VA). UCH, CHCO, and the VA utilize a unified and shared Institutional
Review Board, enabling a robust and compliant system to apply DT program discoveries and benefit patients in
the catchment area, while streamlining access for patients. The DT program continues to focus on advancing
novel compounds developed within UCCC by supporting pilot projects, using the NIH Research Evaluation and
Commercialization Hubs (REACH) program, supporting start-ups, and encouraging SBIR applications. Lastly,
the DT program has fostered strategic recruitments to strengthen its membership to better integrate pediatric,
adult, and companion animal models, impacting patient care across the spectrum of cancer.
摘要
发展治疗学(DT)计划的目标是将基础科学发现转化为临床应用。
适用于所有年龄段的患者,改善集水区患者的生活质量,
超越。成员开发,测试和研究新的治疗方法在成人和儿童患者的固体和
血液恶性肿瘤和领导合作,多机构的倡议,以建立新的治疗
范例DT计划通过改善获得护理的机会和培训下一个
癌症研究人员的一代,专注于指导早期职业教师。DT计划增加了两个
作为先前审查的结果,重点是:1)通过开发
IIT孵化器,并在早期试验和特定疾病组中优先考虑IIT,特别是那些已开发的
被辅导的成员。因此,干预治疗IIT的应计费用从2016年的47增加到2017年的3倍。
2020年140。和2)增强临床前异种移植物开发以促进免疫生物学/免疫疗法
的发现DT资助的试点赠款生产孤儿疾病PDX,结肠直肠癌的人源化模型(HM)
癌症和黑色素瘤中的自体HM。委员会共有78名成员,分别代表18个部门和4所学校,
拥有320万美元的NCI,200万美元的其他NIH和280万美元的其他同行评审资金,同行评审资金增加了50%,
审查研究经费从2016年的540万美元增加到2020年的800万美元。自2016年以来,DT会员注册2688人
641例受试者参与了干预治疗试验,增加了29%。DT成员发布了1000份同行评审
癌症相关论文,其中48%为合作论文(15%为内部论文; 17%为内部论文; 16%为两者),24%为期刊论文
如果大于10。其中47%(47%)代表与其他NCI指定的癌症合作
中心.科罗拉多大学癌症中心(UCCC)教育活动、培训/职业发展
活动和共享资源(SR)支持是DT资助试点赠款优先事项的基础,
强调“本土”疗法和将发现应用于临床。这些投资导致
成功的计划项目合作和跨UCCC的多PI资助。DT继续扩张
UCCC内部以及与包括科罗拉多大学博尔德分校在内的主要合作伙伴的多方利益相关者伙伴关系
(UCB)、科罗拉多州立大学(CSU)、科罗拉多大学医院(UCH)、科罗拉多儿童医院
(CHCO)和退伍军人管理局(VA)。UCH、CHCO和VA利用统一和共享的机构
审查委员会,使一个强大的合规系统能够应用DT项目发现并使患者受益,
集水区,同时简化病人的通道。DT计划继续专注于推进
通过支持试点项目,使用NIH研究评估,
商业化中心(REACH)计划,支持初创企业,并鼓励SBIR应用。最后,
DT计划促进了战略招聘,
成人和伴侣动物模型,影响整个癌症谱的患者护理。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RICHARD D SCHULICK其他文献
RICHARD D SCHULICK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RICHARD D SCHULICK', 18)}}的其他基金
University of Colorado Cancer Center Support Grant - CTRAC Supplement Yr 02
科罗拉多大学癌症中心支持补助金 - CTRAC 补充第 02 年
- 批准号:
10439981 - 财政年份:2021
- 资助金额:
$ 209.1万 - 项目类别:
University of Colorado Cancer Center Support Grant
科罗拉多大学癌症中心支持补助金
- 批准号:
10371494 - 财政年份:2021
- 资助金额:
$ 209.1万 - 项目类别:
Colorado's Partnership to Implement Evidence-Based Interventions to Reduce the Cancer Burden
科罗拉多州合作实施循证干预措施以减少癌症负担
- 批准号:
10409393 - 财政年份:2021
- 资助金额:
$ 209.1万 - 项目类别:
Interferon Signaling and the Differential Malignancy Spectrum of Down Syndrome
干扰素信号转导和唐氏综合症的鉴别恶性肿瘤谱
- 批准号:
9933418 - 财政年份:2019
- 资助金额:
$ 209.1万 - 项目类别:
Listeria Monocytogenes to Treat Hepatic Metastases
单核细胞增生李斯特菌治疗肝转移
- 批准号:
6988218 - 财政年份:2005
- 资助金额:
$ 209.1万 - 项目类别:
Listeria Monocytogenes to Treat Hepatic Metastases
单核细胞增生李斯特菌治疗肝转移
- 批准号:
7228884 - 财政年份:2005
- 资助金额:
$ 209.1万 - 项目类别:
Listeria Monocytogenes to Treat Hepatic Metastases
单核细胞增生李斯特菌治疗肝转移
- 批准号:
7085533 - 财政年份:2005
- 资助金额:
$ 209.1万 - 项目类别:
Listeria Monocytogenes to Treat Hepatic Metastases
单核细胞增生李斯特菌治疗肝转移
- 批准号:
7406622 - 财政年份:2005
- 资助金额:
$ 209.1万 - 项目类别:
Listeria Monocytogenes to Treat Hepatic Metastases
单核细胞增生李斯特菌治疗肝转移
- 批准号:
7590470 - 财政年份:2005
- 资助金额:
$ 209.1万 - 项目类别:
GM-CSF Enhanced Colorectal Cancer Tumor Vaccine Program
GM-CSF增强型结直肠癌肿瘤疫苗计划
- 批准号:
6945464 - 财政年份:2004
- 资助金额:
$ 209.1万 - 项目类别:
相似海外基金
Developing a Young Adult-Mediated Intervention to Increase Colorectal Cancer Screening among Rural Screening Age-Eligible Adults
制定年轻人介导的干预措施,以增加农村符合筛查年龄的成年人的结直肠癌筛查
- 批准号:
10653464 - 财政年份:2023
- 资助金额:
$ 209.1万 - 项目类别:
Doctoral Dissertation Research: Estimating adult age-at-death from the pelvis
博士论文研究:从骨盆估算成人死亡年龄
- 批准号:
2316108 - 财政年份:2023
- 资助金额:
$ 209.1万 - 项目类别:
Standard Grant
Determining age dependent factors driving COVID-19 disease severity using experimental human paediatric and adult models of SARS-CoV-2 infection
使用 SARS-CoV-2 感染的实验性人类儿童和成人模型确定导致 COVID-19 疾病严重程度的年龄依赖因素
- 批准号:
BB/V006738/1 - 财政年份:2020
- 资助金额:
$ 209.1万 - 项目类别:
Research Grant
Transplantation of Adult, Tissue-Specific RPE Stem Cells for Non-exudative Age-related macular degeneration (AMD)
成人组织特异性 RPE 干细胞移植治疗非渗出性年龄相关性黄斑变性 (AMD)
- 批准号:
10294664 - 财政年份:2020
- 资助金额:
$ 209.1万 - 项目类别:
Sex differences in the effect of age on episodic memory-related brain function across the adult lifespan
年龄对成人一生中情景记忆相关脑功能影响的性别差异
- 批准号:
422882 - 财政年份:2019
- 资助金额:
$ 209.1万 - 项目类别:
Operating Grants
Modelling Age- and Sex-related Changes in Gait Coordination Strategies in a Healthy Adult Population Using Principal Component Analysis
使用主成分分析对健康成年人群步态协调策略中与年龄和性别相关的变化进行建模
- 批准号:
430871 - 财政年份:2019
- 资助金额:
$ 209.1万 - 项目类别:
Studentship Programs
Transplantation of Adult, Tissue-Specific RPE Stem Cells as Therapy for Non-exudative Age-Related Macular Degeneration AMD
成人组织特异性 RPE 干细胞移植治疗非渗出性年龄相关性黄斑变性 AMD
- 批准号:
9811094 - 财政年份:2019
- 资助金额:
$ 209.1万 - 项目类别:
Study of pathogenic mechanism of age-dependent chromosome translocation in adult acute lymphoblastic leukemia
成人急性淋巴细胞白血病年龄依赖性染色体易位发病机制研究
- 批准号:
18K16103 - 财政年份:2018
- 资助金额:
$ 209.1万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Doctoral Dissertation Research: Literacy Effects on Language Acquisition and Sentence Processing in Adult L1 and School-Age Heritage Speakers of Spanish
博士论文研究:识字对西班牙语成人母语和学龄传统使用者语言习得和句子处理的影响
- 批准号:
1823881 - 财政年份:2018
- 资助金额:
$ 209.1万 - 项目类别:
Standard Grant
Adult Age-differences in Auditory Selective Attention: The Interplay of Norepinephrine and Rhythmic Neural Activity
成人听觉选择性注意的年龄差异:去甲肾上腺素与节律神经活动的相互作用
- 批准号:
369385245 - 财政年份:2017
- 资助金额:
$ 209.1万 - 项目类别:
Research Grants